DIN 02551691 — SANDOZ TOFACITINIB 5 MG
SANDOZ TOFACITINIB is a tablet of Tofacitinib marketed by SANDOZ CANADA INCORPORATED. The full Tofacitinib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02551691
- Brand name
- SANDOZ TOFACITINIB
- Active ingredient
- Tofacitinib
- Strength
- 5 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- SANDOZ CANADA INCORPORATED
- Health Canada status
- MARKETED
- Drug class
- Janus kinase (JAK) inhibitor (selective immunosuppressant)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Tofacitinib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02530015 | AURO-TOFACITINIB | 10 MG | TABLET | AURO PHARMA INC | MARKETED |
| 02530007 | AURO-TOFACITINIB | 5 MG | TABLET | AURO PHARMA INC | MARKETED |
| 02522896 | JAMP TOFACITINIB | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02522799 | PMS-TOFACITINIB | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED |
| 02551705 | SANDOZ TOFACITINIB | 10 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02511312 | TARO-TOFACITINIB | 10 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED |
| 02511304 | TARO-TOFACITINIB | 5 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED |
| 02553988 | TARO-TOFACITINIB XR | 11 MG | TABLET (EXTENDED-RELEASE) | TARO PHARMACEUTICALS INC | MARKETED |
| 02480786 | XELJANZ | 10 MG | TABLET | PFIZER CANADA ULC | MARKETED |
| 02423898 | XELJANZ | 5 MG | TABLET | PFIZER CANADA ULC | MARKETED |
| 02470608 | XELJANZ XR | 11 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED |